{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:02:00Z","timestamp":1775574120094,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41409-025-02796-8","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:03:02Z","timestamp":1768914182000},"page":"484-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermediate-dose TBI\/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphoma"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1667-4109","authenticated-orcid":false,"given":"Isabelle","family":"Kr\u00e4mer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Brecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0387-1640","authenticated-orcid":false,"given":"Thomas","family":"Luft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6746","authenticated-orcid":false,"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Eichkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Stadtherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2796_CR1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1200\/JCO-25-00183","volume":"43","author":"A de Masson","year":"2025","unstructured":"de Masson A, Beylot-Barry M, Ram-Wolff C, Mear J-B, Dalle S, Rouanet J, et al. Overall survival after allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score-matched controlled prospective study. J Clin Oncol. 2025;43:2461\u20136. JCO2500183.","journal-title":"J Clin Oncol"},{"key":"2796_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/hematology.2024000670","volume":"2024","author":"P Dreger","year":"2024","unstructured":"Dreger P, Schmitz N. The role of stem cell transplant (auto and allo) in PTCL and CTCL. Hematol Am Soc Hematol Educ Program. 2024;2024:69\u201377.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2796_CR3","first-page":"1047","volume":"30","author":"A Goyal","year":"2024","unstructured":"Goyal A, O\u2019Leary D, Dabaja B, Weng W-K, Zain J, Cutler C, et al. ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and sezary syndrome. Transpl Cell Ther. 2024;30:1047\u201360.","journal-title":"Transpl Cell Ther"},{"key":"2796_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41409-025-02522-4","volume":"60","author":"I Kr\u00e4mer","year":"2025","unstructured":"Kr\u00e4mer I, K\u00f6nig L, Luft T, Hegenbart U, Sch\u00f6nland S, Eichkorn T, et al. Intermediate-dose TBI\/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma. Bone Marrow Transpl. 2025;60:581\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2796_CR5","doi-asserted-by":"publisher","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","volume":"195","author":"J Latzka","year":"2023","unstructured":"Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome - Update 2023. Eur J Cancer. 2023;195:113343.","journal-title":"Eur J Cancer"},{"key":"2796_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/hon.2719","volume":"38","author":"T Mori","year":"2020","unstructured":"Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sezary syndrome. Hematol Oncol. 2020;38:266\u201371.","journal-title":"Hematol Oncol"},{"key":"2796_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","volume":"56","author":"E Domingo-Domenech","year":"2021","unstructured":"Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sezary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2021;56:1391\u2013401.","journal-title":"Bone Marrow Transpl"},{"key":"2796_CR8","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1080\/10428194.2020.1790555","volume":"61","author":"I Isufi","year":"2020","unstructured":"Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, et al. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leuk Lymphoma. 2020;61:2955\u201361.","journal-title":"Leuk Lymphoma"},{"key":"2796_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2991\/chi.k.210529.001","volume":"3","author":"M Stamouli","year":"2021","unstructured":"Stamouli M, Gkirkas K, Karagiannidi A, Iliakis T, Chondropoulos S, Thomopoulos T, et al. Allogeneic stem cell transplantation with a novel reduced intensity conditioning regimen for the treatment of patients with primary cutaneous T-cell lymphomas. Clin Hematol Int. 2021;3:72\u201376.","journal-title":"Clin Hematol Int"},{"key":"2796_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41409-023-02122-0","volume":"59","author":"A Goyal","year":"2024","unstructured":"Goyal A, O\u2019Leary D, Foss F. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis. Bone Marrow Transpl. 2024;59:41\u201351.","journal-title":"Bone Marrow Transpl"},{"key":"2796_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02696-x.1","author":"G Damaj","year":"2025","unstructured":"Damaj G, de Masson A, Dreger P, Bazarbachi A, Berning P, Corradini P, et al. Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee. Bone Marrow Transpl. 2025. https:\/\/doi.org\/10.1038\/s41409-025-02696-x.1.","journal-title":"Bone Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02796-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02796-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02796-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:19:54Z","timestamp":1775571594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02796-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2796"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02796-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IK reports honoraria for talks from AbbVie, AstraZeneca, Lilly, Incyte and for advisory board participation from\u00a0Janssen-Cilag GmbH (J&J), Lilly and SOBi (partly to institution); training and travel grant from Janssen-Cilag, Roche, SOBi; congress participation fee from Abbvie, Johnson&Johnson, Lilly, SOBi. JCH reports honoraria for talks from BMS, Delcath, Immunocore, MSD, Novartis, Pierre Fabre, Sanofi and Sunpharma and honoraria for advisory board participation from Onkowissen and Sunpharma. UH reports honorarium for talks: Janssen, Pfizer, Alnylam, Akcea, Prothena, Astra Zeneca; financial support of congress participation: Janssen, Prothena, Pfizer; advisory boards: Pfizer, Prothena, Janssen, Alexion; financial sponsoring of Amyloidosis Registry: Janssen. Peter Dreger reports consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speakers bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); research support from Riemser (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent to data collection and scientific evaluation before admission to alloHCT. Data analysis was approved by the institutional review board (Ethics Committee of the Medical Faculty of Heidelberg University, S-200\/2010).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}